Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results

By Yahoo! Finance   |   3 weeks ago
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results

Metsera, Inc. (NASDAQ:MTSR) shows promising Phase 1 results for MET-233i, an amylin analog with significant weight loss effects. The company aims to develop innovative treatments for obesity and metabolic diseases, positioning itself as a high-potential biotech stock.

Read More

Did you find this insightful?